Search
Bavtavirine
go.drugbank.com/drugs/DB21527InvestigationalThe usage of the INN stem '-virine' in the name indicates that Bavtavirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Cenacitinib
go.drugbank.com/drugs/DB21735InvestigationalThe usage of the INN stem '-citinib' in the name indicates that Cenacitinib is a Janus kinase inhibitor.
Phospholipid-transporting ATPase IA
go.drugbank.com/bio_entities/BE0001001TargetHumansCatalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures … The flippase complex ATP8A1:CDC50A seems to play a role in regulation of cell migration probably involving flippase-mediated translocation of phosphatidylethanolamine (PE) at the cell membrane (By similarity
Synonyms: P4-ATPase flippase complex alpha subunit ATP8A1Phospholipid-transporting ATPase VA
go.drugbank.com/bio_entities/BE0011629TransporterHumansCatalytic component of P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of phosphatidylcholine (PC) from the outer to the inner leaflet of the plasma membrane
Synonyms: P4-ATPase flippase complex alpha subunit ATP10AUlevostinag
go.drugbank.com/drugs/DB14721InvestigationalSpecifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs).
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular … [L43987] Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages.
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16923ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB22669ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes
Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB22671ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes